InVivoSIM anti-human C5 (Eculizumab Biosimilar)
| Clone | Eculizumab | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Catalog # | SIM0011 | ||||||||||||
| Category | InVivoSIM™ Biosimilar Antibodies | ||||||||||||
| Price |
|
This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Eculizumab making it ideal for research use. This Eculizumab biosimilar reacts with human terminal complement component 5 (C5). C5 is a precursor protein synthesized in the liver. During complement activation, C5 is cleaved, producing two disulfide linked glycoproteins C5α and C5β. C5α is further cleaved by C5 convertase into C5a and C5α', the latter binds to C5β to form C5b, which in turn sequentially recruits C6-C9 to form the membrane attack complex (MAC). MAC destroys pathogens by forming a lytic pore in their membrane. Eculizumab inhibits the cleavage of C5 to C5α and C5β. Eculizumab is used for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
| Isotype | human IgG4 |
| Recommended Isotype Control(s) | InVivoMAb human IgG4 (S228P) isotype control, anti-hen egg lysozyme |
| Recommended Dilution Buffer | InVivoPure™ pH 7.0 Dilution Buffer |
| Immunogen | Human C5 |
| Reported Applications |
|
| Formulation |
|
| Endotoxin |
|
| Aggregation |
|
| Purity |
|
| Sterility | 0.2 μM filtered |
| Production | Purified from cell culture supernatant |
| Purification | Protein A |
| Molecular Weight | 150 kDa |
| Murine Pathogen Test Results |
|
| Storage | The antibody solution should be stored at the stock concentration at 4°C. Do not freeze. |
하단영역
(ZIP code : 07532) 902, 9F Hanwha bizmetro 1-cha, 551-17 YangcheonRo,
Gayang-dong, Gangseo-Gu, Seoul, Korea
TEL : 02-2013-8240
FAX : 02-2013-8243
Email : bioxcell@bioxcell.co.kr
Copyright by 2020 BioXCell Korea. All Rights Reserved.
- BioXCell Korea
- Opening hours
- Monday - Friday 9AM - 6PM
- Follow Us
-
